Literature DB >> 26988569

Reliability Assurance of Detection of EML4-ALK Rearrangement in Non-Small Cell Lung Cancer: The Results of Proficiency Testing in China.

Yulong Li1, Rui Zhang2, Rongxue Peng1, Jiansheng Ding1, Yanxi Han2, Guojing Wang1, Kuo Zhang2, Guigao Lin2, Jinming Li3.   

Abstract

INTRODUCTION: Currently, several approaches are being used to detect echinoderm microtubule associated protein like 4 gene (EML4)-anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement, but the performance of laboratories in China is unknown. To evaluate the proficiency of different laboratories in detecting EML4-ALK rearrangement, we organized a proficiency test (PT).
METHODS: We prepared formalin-fixed, paraffin-embedded samples derived from the xenograft tumor tissue of three non-small cell lung cancer cell lines with different EML4-ALK rearrangements and used PTs to evaluate the detection performance of laboratories in China.
RESULTS: We received results from 94 laboratories that used different methods. Of the participants, 75.53% correctly identified all samples in the PT panel. Among the errors made by participants, false-negative errors were likely to occur. According to the methodology applied, 82.86%, 76.67%, 77.78%, and 66.67% of laboratories using reverse transcriptase polymerase chain reaction, fluorescence in situ hybridization, next-generation sequencing, and immunohistochemical analysis, respectively, could analyze all the samples correctly. Moreover, we have found that the laboratories' genotyping capacity is high, especially for variant 3.
CONCLUSION: Our PT survey revealed that the performance and methodological problems of laboratories must be addressed to further increase the reproducibility and accuracy of detection of EML4-ALK rearrangement to ensure reliable results for selection of appropriate patients.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EML4-ALK rearrangement; Non–small cell lung cancer; Proficiency testing; Xenograft

Mesh:

Substances:

Year:  2016        PMID: 26988569     DOI: 10.1016/j.jtho.2016.03.004

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  4 in total

Review 1.  Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets.

Authors:  Mercedes L Dalurzo; Alejandro Avilés-Salas; Fernando Augusto Soares; Yingyong Hou; Yuan Li; Anna Stroganova; Büge Öz; Arif Abdillah; Hui Wan; Yoon-La Choi
Journal:  Onco Targets Ther       Date:  2021-09-01       Impact factor: 4.345

Review 2.  ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

3.  Case Report: A Pregnant Woman Diagnosed as ALK-Rearrangement Lung Large Cell Neuroendocrine Cancer With Brain Metastasis.

Authors:  Zaixiang Fu; Ganggui Zhu; Liquan Wang; Shen Hu; Lu Cheng; Fuyi Liu
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

4.  The reliable assurance of detecting somatic mutations in cancer-related genes by next-generation sequencing: the results of external quality assessment in China.

Authors:  Rui Zhang; Jiansheng Ding; Yanxi Han; Lang Yi; Jiehong Xie; Xin Yang; Gaowei Fan; Guojing Wang; Mingju Hao; Dong Zhang; Kuo Zhang; Guigao Lin; Jinming Li
Journal:  Oncotarget       Date:  2016-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.